Artificial intelligence (AI) and machine learning (ML) have potential to revolutionise cell and gene therapy (CGT), from patient recruitment to supply chain optimisation. Up to 90% of AI/ML models do not make it into production due to challenges in data handling and regulatory hurdles. CGT developers looking to adopt AI must ensure they are aware of these issues and address challenges relating to data availability, limitations in data access, algorithm validation and security.
Y chromosome loss creates hidden cancer vulnerability in men
A study initiated by a University of Arizona Cancer Center physician-scientist Dr. Dan Theodorescu revealed that the loss of the Y chromosome in men’s body
